DOJ Reevaluates Cannabis and Gun Prosecutions as Federal Policy Shifts

The Department of Justice is actively reconsidering its approach to prosecuting marijuana users who possess firearms, signaling a potential shift in federal enforcement priorities. Acting Attorney General Todd Blanche confirmed this development as the Trump administration introduces new measures intended to ease regulations on gun owners and businesses. The intersection of cannabis use and gun rights has long been a contentious legal gray area, with federal law prohibiting marijuana consumers from owning firearms despite state-level legalization. "Of course" the DOJ is rethinking these prosecutions, Blanche stated, reflecting growing pressure to reconcile conflicting policies as cannabis laws evolve nationwide

In related policy news, President Donald Trump’s nominee for surgeon general, Dr. Nicole Saphier, has taken a nuanced stance on marijuana. While she has expressed concern over certain health risks, including what she described as a link between cannabis use and gynecomastia, Saphier has also acknowledged the medical potential of cannabis. "Medical cannabis does have potential benefits," Saphier admitted, indicating that the administration’s approach may balance caution with openness to legitimate therapeutic uses. This comes at a time when federal agencies and lawmakers are increasingly pressed to clarify their positions amid rapid changes in public opinion and state laws

Meanwhile, the House of Representatives passed a new Farm Bill containing provisions to reduce regulatory burdens for industrial hemp producers, though it notably omitted measures to delay or revise the pending federal recriminalization of hemp-derived THC products set for later this year. The ongoing debate over hemp and cannabis regulation is further complicated by a House Appropriations Subcommittee move to block the Department of Justice from rescheduling marijuana, directly opposing the Trump administration’s reform efforts. The House Appropriations Committee also expressed concerns about health risks associated with cannabis products, while simultaneously encouraging expanded research into the therapeutic benefits of psychedelics

State-level developments continue to reflect the complexity of cannabis policy in the U.S. Oklahoma’s attorney general reaffirmed a commitment to federal-local cooperation on law enforcement, while Hawaii’s medical cannabis regulator welcomed federal rescheduling as a means to facilitate more research. Minnesota, meanwhile, is opening applications for cannabis farmer training and loan grant programs, showcasing the economic opportunities emerging in newly regulated markets. On the scientific front, recent studies have highlighted cannabis sativa stems as a promising anti-cancer agent and found that CBD may counteract age-related cognitive decline in animal models

Public opinion is also shifting, with a recent Texas poll indicating majority support for marijuana legalization across several counties. In the business sector, Vireo Growth Inc. is set to acquire FLUENT Corp., and Verano Holdings Corp. reported $208.2 million in quarterly net revenue despite a net loss. From the OG Lab newsroom perspective, these federal and state-level shifts in policy and enforcement mark a pivotal moment for the cannabis industry. The DOJ’s reconsideration of cannabis and gun prosecutions could have wide-reaching effects, and industry stakeholders should closely monitor how federal, state, and scientific developments converge to shape the next phase of cannabis regulation and business growth